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Abstract
Background: Transcatheter left atrial appendage closure (LAAC) is performed either in conscious 
sedation (CS) or general anesthesia (GA), and limited data exist regarding clinical outcomes for the 
two approaches. The aim of the study was to analyze the effect of CS versus GA on acute outcomes in  
a large patient cohort undergoing LAAC with a Watchman occluder. 
Methods: A cohort of 521 consecutive patients underwent LAAC with Watchman occluders at two 
centers (REGIOMED hospitals, Germany) between 2012 and 2018. One site performed 303 consecutive 
LAAC procedures in GA, and the other site performed 218 consecutive procedures in CS. The safety 
endpoint was a composite of major periprocedural complications and postoperative pneumonia. The 
efficacy endpoint was defined as device success.
Results: After a 1:1 propensity score matching, 196 (CS) vs. 115 (GA) patients could be compared.  
In 5 (2.6%) cases CS was converted to GA. The primary safety endpoint (3.5% [CS] vs. 7.0% [GA],  
p = 0.18) and its components (major periprocedural complications: 2.5% vs. 3.5%, p = 0.73; postopera-
tive pneumonia: 2.6% vs. 4.3%, p = 0.51) did not differ between the groups. Also, device success was 
comparable (96.9% vs. 93.9%, p = 0.24).
Conclusions: In patients undergoing LAAC with the Watchman device, conscious sedation and gen-
eral anesthesia showed comparable device success rates and safety outcomes. The type of anesthesia for 
LAAC may therefore be tailored to patient comorbidities, operator experience, and hospital logistics. 
(Cardiol J 2021; 28, 4: 519–527)
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Left atrial appendage closure (LAAC) is a de-
vice-based method for stroke prevention in patients 
with atrial fibrillation (AF), who have absolute or 
relative contraindications for oral anticoagulation 
(OAC) [1, 2]. Substantial evidence exists for the 
Watchman occluder (Boston Scientific, Marlbor-
ough, MA, US), which has been in clinical use since 
2005. Compared to warfarin, it provides compara-
ble efficacy in long-term prevention of all-cause 
stroke. Furthermore, it reduces cardiovascular 
mortality and major bleeding events, particularly 
hemorrhagic stroke [3]. Because LAAC is a purely 
preventive treatment, without any immediate 
benefit for the patient, it is mandatory to keep 
periprocedural complications as low as possible. 
Due to the complex anatomy and topography of the 
left atrial appendage (LAA), the procedure can be 
demanding. Procedural success and adverse events 
depend on several factors, such as patient char-
acteristics and comorbidities, experience of the 
operating physician and team, technical features 
of the device, intraprocedural cardiac imaging, and 
possibly the type of anesthesia. Most centers prefer 
procedural guidance by transesophageal echocar-
diography (TEE), which requires either sedation 
or full anesthesia to improve patient comfort and 
tolerance of the TEE probe. One option is general 
anesthesia (GA), which allows control of airways, 
ventilation, and patient movement. The other is 
conscious sedation (CS) with the patient spontane-
ously breathing. Previous studies investigating the 
type of anesthesia used during other heart disease 
interventions could not establish superiority of any 
one method but documented shorter postoperative 
monitoring or length of hospital stay in CS [4–10]. 
Data on the impact of CS or GA on periprocedural 
outcomes in LAAC are lacking. Therefore, the aim 
of this study was to compare both methods with 
regard to device success and major periprocedural 
complications, including postoperative pneumonia, 
as well as length of postoperative monitoring based 




All consecutive patients, who underwent 
LAAC with Watchman occluders at two centers 
(REGIOMED hospitals Coburg and Lichtenfels, 
Germany), were prospectively enrolled in an ob-
servational registry. At the Lichtenfels site, where 
inclusion started in 2012, all patients were treated 
exclusively under GA. The Watchman program at 
the Coburg site started in 2016, and all interven-
tions were performed primarily under conscious 
sedation (Fig. 1). Indications for LAAC were based 
on current guidelines and recommendations [1, 2]. 
Exclusion criteria were active infection, pregnancy, 
and indications for OAC other than AF. A retrospec-
tive post-hoc analysis of demographic character-
istics, procedural data, and clinical outcomes was 
performed for all patients in a standardized manner. 
Adverse events were adjudicated by a clinical event 
committee of two independent physicians and, in 
cases of disagreement, by a third referee. The study 
complies with the Declaration of Helsinki. It was 
conducted according to local ethical standards and 
requirements, and all patients provided written 
informed consent. 
LAAC procedure 
The characteristics of the Watchman device 
and procedural aspects were previously described 
in detail [11]. Generally, the occluder was im-
planted via a transseptal puncture and use of 
a delivery sheath. In both groups, all procedures 
were performed in a catheterization laboratory 
and were both guided by TEE and fluoroscopy. 
However, procedural settings, postoperative 
monitoring, and antithrombotic medical therapy 
differed between the two centers: For the GA 
group, the team comprised 3 to 4 doctors (1 or 
2 interventional cardiologists, one TEE guide, 
one anesthesiologist) and 4 nurses (Fig. 2). All 
patients were orotracheally intubated and me-
chanically ventilated. In the majority of cases, the 
anesthesia was a combination of propofol and an 
opioid (fentanyl or remifentanil). Extubation was 
aimed to be performed in the catheterization labo-
ratory immediately after the procedure, whenever 
possible. The standard protocol provided a postop-
erative monitoring in the intermediate care (IMC) 
unit for 24 hours. According to the PROTECT-AF 
study, postoperative antithrombotic therapy con-
sisted of OAC plus acetylsalicylic acid (ASA) for 
45 days followed by dual antiplatelet therapy 
with ASA and clopidogrel for 6 months [12]. In 
the CS group, the operating team consisted of 
3 cardiologists (2 interventionalists, 1 TEE guide) 
and 3 nurses, all with expertise in propofol seda-
tion and intensive care unit (ICU) skills (Fig. 2). 
All patients received local anesthesia with mepiv-
acaine 1% at the puncture site and lidocaine pump 
spray for introduction of the TEE probe. Patients 
were spontaneously breathing, and conversion to 
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GA was only performed in case of respiratory or 
hemodynamic instability. For sedation, a 1–5 mg 
bolus of midazolam was administered. In addi-
tion, propofol was administered continuously at 
the lowest dose possible. The standard protocol 
required 4 hours of postoperative monitoring in 
the IMC unit. The postprocedural antithrombotic 
regimen consisted of dual antiplatelet therapy 
with ASA and clopidogrel for 3 months. 
Definitions and endpoints
Demographic, clinical, and procedural charac-
teristics, as well as adverse events and endpoints, 
were reported according to the current recommen-
dations of the European Heart Rhythm Association 
and the European Association of Percutaneous 
Cardiovascular Interventions, the Bleeding Aca-
demic Research Consortium (BARC), the Valve 
Academic Research Consortium criteria, and the 
Cardiovascular and Stroke Endpoint Definitions 
for Clinical Trials [13–16]. Device success was 
defined as correct deployment and implantation of 
the LAA occluder. Major periprocedural complica-
tions included death (< 72 hours after the index 
procedure), stroke, device embolization, cardiac 
tamponade or pericardial effusion requiring inter-
vention, major bleeding (> BARC type 3a), need 
for bailout surgery, need for cardio-pulmonary 
resuscitation, severe kidney injury, and other rel-
evant complications leading to prolonged hospital 
stay. The safety endpoint was a composite of the 
mentioned major periprocedural complications and 
postoperative pneumonia. The efficacy endpoint 
was defined as device success. 
Statistical analysis 
Statistical analyses were performed with the 
Graph Pad Prism 8 software (GraphPad Inc. La 
Jolla, California, USA). Categorical variables are 
presented as actual numbers and percentages and 
compared using the Fisher’s exact test. Continu-
ous variables are summarized as mean ± standard 
deviation (SD) or as medians with corresponding 
interquartile range (IQR) and compared using an 
unpaired t-test. Findings were considered statis-
tically significant at the 0.05 level. We performed 
a propensity score matching for the likelihood of 
performing LAAC under conscious sedation or 
general anesthesia with a ratio of 1:1 with replace-
ment using the R software, the package “MatchIt” 
and “cobalt” [17–19]. The quality of the matching 
was assessed in two ways: there was a standardized 
difference of < 0.10 for each baseline covariable 
and there was no significant difference in the co-
variables among the two groups using a univariate 
logistic regression or unpaired t-test.
Results
Patient characteristics
Between November 2016 and May 2018, 218 
patients underwent LAAC with Watchman occlud-
ers under CS at the Coburg site, and respectively 
303 received Watchman devices under GA at the 
Lichtenfels site, between February 2012 and April 
2017. After a 1:1 propensity score matching, 196 
(CS) vs. 115 (GA) patients were compared (Fig. 1). 
Baseline characteristics are shown in Table 1. The 
prevalence of female gender (49.0% [CS] vs. 36.5% 
521 patients undergoing Watchman left atrial appendage closure at 2 centers
1:1 propensity score matching
Safety endpoint:
Major periprocedural complications and postoperative pneumonia
Efcacy endpoint:
Device success








Figure 1. Study flow chart. 
www.cardiologyjournal.org 521
Caroline Kleinecke et al., Conscious sedation vs. general anesthesia in laaC
[GA], p = 0.03) and arterial hypertension (94.4% 
vs. 87.8%, p = 0.04) was higher in the CS group. 
The rate of permanent/persistent AF (53.6% vs. 
67.0%, p = 0.02) and liver disease (6.1% vs. 14.8%, 
p = 0.01) was higher in the GA group. All other 
baseline characteristics were comparable, espe-
cially age (78.0 ±7.3 [CS] vs. 77.0 ± 6.8 [GA], p = 
= 0.23), stroke and bleeding risk (CHA2DS2-VASC 
score: 4.8 ± 1.4 vs. 4.6 ± 1.7, p = 0.40; HAS-BLED 
score: 3.4 ± 0.8 vs. 3.4 ± 0.9, p = 0.63), as well as 
renal function (glomerular filtration rate [mL/min]: 
55.3 ± 26.0 vs. 56.2 ± 22.8, p = 0.75) and severe 
lung disease (7.1% vs. 9.6%, p = 0.52).
Procedural characteristics 
Procedural aspects are depicted in Table 2. 
All interventions were guided by TEE, apart from 
1 case of intracardiac echocardiography in the CS 
group. In the CS group the rate of implantation 
attempts (1.2 ± 0.6 [CS] vs. 1.6 ± 0.9 [GA], p ≤ 
≤ 0.001) and use of contrast media were lower 
(median, mL: 50 [IQR 30–60] vs. 90 [IQR 70–113], 
p ≤ 0.001); furthermore, fluoroscopy (median, min: 
7 [IQR 5–10] vs. 10 [IQR 7–19], p ≤ 0.001) and 
procedure (median, min: 41 [IQR 35–55] vs. 49 
[IQR 38–65], p = 0.02) times were shorter. In 
5 (2.6%) patients CS was converted to GA: in 
1 case due to LAA perforation with cardiogenic 
shock, in another due to epistaxis with aspira-
tion, and in 3 patients due to respiratory failure. 
The primary safety endpoint (3.5% [CS] vs. 7.0% 
[GA], p = 0.18) did not differ significantly between 
the groups. Also, its components, postoperative 
pneumonia (2.6% vs. 4.3%, p = 0.51), and major 
periprocedural complications (2.5% vs. 3.5%, 
p = 0.73) were comparable (Fig. 3). 
In the CS group, 1 case of procedure-related 
death occurred in an 87-year-old, female patient, 
who suffered from a major stroke shortly after the 
intervention. Cerebral computed tomography after 
24 hours demonstrated relevant ischemic cerebral 
infarction, and the patient died 3 days after the 
index procedure. Device success was comparable 
between the groups (96.9% vs. 93.9%, p = 0.24). 
As provided by the standard protocol of each center, 
postoperative monitoring was significantly shorter 
in the CS group (median, hours: 4.0 ± 59.9 vs. 
24.0 ± 10.8, p = 0.03; Fig. 3). Both groups show 
large standard deviations due to patients with 
periprocedural complications, who were treated 
for several days or weeks in the ICU. 
TEE follow-up and 30-day mortality 
Due to logistic reasons, the TEE follow-up rate 
is incomplete in the CS group and differs between 
the groups (62.2% [CS] vs. 100% [GA], p ≤ 0.0001) 
(Table 3). Therefore, a numerically lower rate of 
device-related thrombus was observed in the CS 
Table 1. Baseline characteristics.
Conscious sedation  
(n = 196)
General anesthesia  
(n = 115)
P
Age at time of LAAC [years] 78.0 ± 7.3 77.0 ± 6.8 0.23
Female gender 96 (49.0%) 42 (36.5%) 0.03
Body mass index [kg/m2] 29.7 ± 6.4 29.5 ± 5.1 0.69
Permanent/persistent AF 105 (53.6%) 77 (67.0%) 0.02
Arterial hypertension 185 (94.4%) 101 (87.8%) 0.04
Diabetes mellitus 67 (34.2%) 40 (34.8%) 0.91
Coronary artery disease 113 (57.7%) 60 (52.2%) 0.35
Prior PCI/CAGB 88 (44.9%) 47 (40.9%) 0.49
LVEF [%] 53.1 ± 11.9 55.1 ± 9.5 0.12
Congestive heart failure 59 (30.1%) 29 (25.2%) 0.36
Glomerular filtration rate [mL/min] 55.3 ± 26.0 56.2 ± 22.8 0.75
Severe lung disease 14 (7.1%) 11 (9.6%) 0.45
Liver disease 12 (6.1%) 17 (14.8%) 0.01
CHA2DS2-VASc score 4.8 ± 1.4 4.6 ± 1.7 0.40
HAS-BLED score 3.4 ± 0.8 3.4 ± 0.9 0.63
Categorical variables are expressed as frequencies (n) and percentages (%). Continuous data is reported as mean and standard deviation;  
AF — atrial fibrillation; CABG — coronary artery bypass grafting; LAAC — left atrial appendage closure; LVEF — left ventricular ejection fraction; 
PCI — percutaneous coronary intervention
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group (0.8% vs. 5.2%, p = 0.01). The rate of major 
peri-device leaks (≥ 5 mm) was comparable between 
the groups (2.8% vs. 1.4%, p = 0.47). Thirty-day 
mortality was similar for both groups (3.6% vs. 
1.4%, p = 0.47) (Fig. 4): In the CS group, 7 patients 
had died at 30-day follow-up for the following rea-
sons: unexplained death (80 and 88 years old, both 
male), heart failure (85 and 75 years old, both male), 
liver failure (70 years old, male), pancreatic cancer 
(86 years old, male), and stroke (87 years old, fe-
male). In the GA group, a 71-year-old male patient 
died due to unexplained reasons, a 70-year-old male 
patient due to pneumonia 3 weeks after the index 
procedure, and an 87-year-old female patient due 
to spontaneous retroperitoneal hematoma 25 days 
after the index procedure. 
Discussion
Over the last decade, LAAC has become an 
accepted procedure and is offered in many centers. 
Commonly, procedural imaging is necessary to 
guide this often complex intervention. One guid-
ing tool is intracardiac echocardiography, which 
avoids anesthesia and its associated potential risks. 
However, most centers use TEE, which is widely 
available, less expensive, and offers superior imag-
ing quality. In many centers, general anesthesia is 
used to improve patient comfort and tolerance to 
the procedure.
Currently, there are limited data regarding the 
impact of the anesthesiologic strategy in LAAC 
on procedural, peri-procedural, and later clinical 
outcomes: A case series in 11 patients investigated 
LAAC under sedation and noninvasive ventilation 
[20]. In all patients, clinical outcome was unevent-
ful, with a high degree of satisfaction of the medical 
team.
The present study is the first that directly 
compares CS and GA for LAAC with Watchman oc-
cluders based on the results of propensity-matched 
data from two real-world registries. 
Our main findings are: (1) CS and GA are 
equally effective for device success; (2) both meth-
Table 2. Procedural characteristics.
Conscious sedation  
(n = 196)
General anesthesia  
(n = 115)
P
Conversion from CS to GA 5 (2.6%)
TEE guidance 194 (99.5%) 115 (100.0%) 0.44
Device success 190 (96.9%) 108 (93.9%) 0.20
Implantation attempts 1.2 ± 0.6 1.6 ± 0.9 < 0.0001
Fluoroscopy time [min] 7 (IQR 5–10) 10 (IQR 7–19) < 0.0001
Procedure time [min] 41 (IQR 35–55) 49 (IQR 38–65) 0.0002
Total contrast volume [mL] 50 (IQR 30–60) 90 (IQR 70–113) < 0.0001
Postoperative monitoring [h] 4 (IQR 4-4) 24 (IQR 22–24) 0.03
Length of hospital stay [days] 13 (IQR 6–16) 3 (IQR 3–8) < 0.0001
Primary safety endpoint 7 (3.5%) 8 (7.0%) 0.18
Postoperative pneumonia 5 (2.6%) 5 (4.3%) 0.39
Major periprocedural complication: 5 (2.5%) 4 (3.5%) 0.64
Death 1 (0.5%) 0 (0.0%) 0.44
Stroke 1 (0.5%) 0 (0.0%) 0.44
Pericardial tamponade 2 (1.0%) 4 (3.5%) 0.13
Major bleeding 3 (1.5%) 4 (3.5%) 0.26
Major access vessel complication 1 (0.5%) 1 (0.9%) 0.70
Need for bailout surgery 0 (0.0%) 0 (0.0%) 1.0
Device embolization 0 (0.0%) 0 (0.0%) 1.0
Severe kidney injury 0 (0.0%) 1 (0.9%) 0.44
Cardiogenic shock 2 (1.0%) 0 (0.0%) 0.28
Need for cardiopulmonary resuscitation 1 (2.5%) 0 (0.0%) 0.28
Categorical variables are expressed as frequencies (n) and percentages (%). Continuous data is reported as mean and standard deviation or as 
median and interquartile range; CS — conscious sedation; GA — general anesthesia; TEE — transesophageal echocardiography
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Figure 3. Key variables of periprocedural outcomes; A. Major periprocedural complications; B. Postoperative pneu-
monia; C. Device success; D. Postoperative monitoring; CS — conscious sedation; GA — general anesthesia.
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ods offer comparable safety with regard to major 
periprocedural complications and postoperative 
pneumonia; (3) the type of anesthesia does not af-
fect 30-day mortality; and (4) CS requires shorter 
postoperative monitoring and less personal and 
logistic resources.
These observations are in line with other stud-
ies that investigated the impact of CS and GA on 
outcomes in other structural interventions such as 
percutaneous mitral valve repair or transcatheter 
aortic valve implantation (TAVI) [4–10]. Those 
studies report no differences in procedural success 
or clinical outcomes according to the type of an-
esthesia. In the present study, device success was 
comparable to the implant success rate (95.8%) of 
the worldwide largest National Cardiovascular Data 
Registry (NCDR) with 38,158 procedures, captured 
between 2016 and 2018 [21]. The NCDR reports 
a fairly low rate of major periprocedural complica-
tions (1.9%). The rates of adverse events in our 
cohorts are higher, which may be attributable to 
the older and more polymorbid patient population 
of our study with higher CHA2DS2-VASc and HAS-
-BLED scores and the much shorter timeframe of 
treatment starting from 2012. 
Similar to our results, the German Aortic Valve 
Registry reported shorter procedure and fluoros-
copy times for CS [9]. The United States post-Food 
and Drug Administration approval Watchman reg-
istry of 3822 patients reported a median procedure 
time of 50 min [22]. In comparison, our results with 
a median of 49 min for the GA and 41 min for the 
CS group are comparable. Despite speedier inter-
ventions in our CS group arm, we observed fewer 
implantation attempts and lower contrast volume 
in this group. The most likely reason for this is that 
in the GA group patient enrollment started 4 years 
earlier, which affects expertise with the procedure 
and explains the differences in operation times, 
contrast use, and implantation attempts between 
our two groups. The PROTECT-AF trial and the 
continued access registry showed — as in all in-
terventional procedures — a learning curve of the 
performing teams with a substantial improvement 
in procedural speed and success, as well as a signifi-
cant decrease in procedure-related complications 
[23]. However, another potential reason for these 
findings may be the type of anesthesia: General 
anesthesia avoids excess salivary secretion and 
consequent coughing and unexpected moving. 
This enables a more meticulous transseptal punc-
ture, several measurements of the LAA, as well 
as repetitive re-positioning or replacement of the 
device if necessary. Therefore, GA is often deemed 
more appropriate for operators and hospitals at the 
beginning of their learning curves, whereas CS, 
which considerably streamlines the procedure, 
is a valuable option for high-volume centers with 
experienced operators and teams. 
As outlined, in our CS group, 5 (2.6%) patients 
had to be converted to GA. Respiratory failure with 
the need for temporary non-invasive ventilation 
or orotracheal intubation is a common adverse ef-
fect of deep conscious sedation, but most of these 
cases recover rapidly and uneventfully. Indeed, all 
Figure 4. 30-day mortality; CS — conscious sedation; 
GA — general anesthesia.
Table 3. Transesophageal echocardiography (TEE) follow-up and 30-day mortality.
Conscious sedation  
(n = 196)
General anesthesia  
(n = 115)
P
TEE performed 122 (62.2%) 115 (100.0%) < 0.0001
Device-related thrombus 1 (0.8%) 6 (5.2%) 0.01
Peri-device leak (≥ 5 mm) 9 (8.6%) 9 (7.8%) 0.24
30-day mortality 7 (3.6%) 3 (1.4%) 0.47
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3 patients who suffered respiratory depression 
could be extubated on the same day. Despite choos-
ing CS as the primary anesthesiologic approach, 
the team has to be prepared for speedy conversion 
to GA if necessary. In a single logistic regression 
analysis, we were unable to detect any predictors 
for respiratory depression in our group, which is 
due to the low numbers. 
Conceptually, CS might be associated with an 
increased aspiration risk caused by hypersalivation 
due to the TEE probe. However, studies investigat-
ing GA and CS in patients undergoing percutaneous 
mitral valve repair observed no differences regard-
ing the development of postoperative pneumonia, 
which is similar to our findings [4, 6]. In those 
studies, the rate of postoperative pneumonia varied 
between 3.3% and 6.7%, which is comparable to 
the rate observed in the present study, in which all 
patients received peri-interventional prophylactic 
antibiotics according to the guidelines. Also, for 
postoperative pneumonia and due to the low event 
rates, we found no relevant predictors in the logis-
tic regression analysis. 
With regard to 30-day mortality, rates were 
comparable between the groups but higher than 
observed in the EWOLUTION registry (0.4%) 
[24]. Nonetheless, after 1 year, the EWOLUTION 
registry reported a relatively high mortality rate 
of 9.8%, reflecting the elderly, fragile, and mul-
timorbid LAAC patient population in European 
countries [25]. Individual patient characteristics 
such as biological and social status, the burden 
of comorbidities, quality of life, frailty, and an-
ticipated residual lifespan should be considered 
when planning LAAC in elderly patients. With 
regard to postoperative monitoring, the standard 
protocol of the two centers required 4 hours 
for CS and 24 hours for GA. Other investiga-
tions documented consistently shorter IMC/ICU 
hours after CS only [4–10]. In addition, Toppen 
et al. [7] reported a higher quality of life at 30-
-day follow-up and a decrease in direct costs in 
patients, who received TAVI under CS. How-
ever, shorter postoperative monitoring seems 
not to affect overall length of hospital stay [4]. 
In the present study, in the GA group LAAC was 
performed as an elective procedure, whereas in 
the CS group patients were mostly hospitalized 
for other reasons, which is clearly the reason for 
the longer hospital stay in the latter group.
Limitations of the study
Due to its retrospective, non-randomized, and 
observational design, as well as the different proce-
dural settings of the GA and CS groups, the present 
study has several limitations. Due to its relatively 
small sample size, our study was not powered 
to detect differences in procedural and clinical 
outcomes. Despite good comparability of the two 
groups with regard to baseline characteristic due 
to propensity score matching, confounders may 
persist, e.g. differences in the rates of gender, arte-
rial hypertension, permanent AF, and liver disease. 
Furthermore and importantly, at the Lichtenfels 
site, patient enrollment started 4 years earlier and 
included the learning curve of the center, which 
likely impacted on the longer intervention and 
fluoroscopy times, as well as more implantation 
attempts and the use of greater amounts of contrast 
volume in this group. Regarding TEE follow-up, 
it was incomplete in the CS group and was not 
analyzed in a core laboratory, which may have led 
to an underreporting of device-related thrombus 
and peri-device leaks in this group. 
Conclusions
In patients undergoing LAAC with the Watch-
man occluder, general anesthesia and conscious 
sedation provided comparable safety, efficacy, and 
device success, but CS shortened postoperative 
monitoring. Therefore, the type of anesthesia for 
LAAC may be tailored to patient characteristics, 
operator experience, and hospital logistics. 
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